Researchers strive to find optimal approach for reducing toxicities resulting from graft-versus-host-disease prophylaxis treatment.Read More
Immune checkpoint inhibitors are showing promise in advanced renal, lung and skin cancers, temporarily inhibiting modulating mechanisms in patients’ immune systems to allow a robust response against cancer cells.
A Cleveland Clinic cancer researcher discusses how next generation sequencing technology is poised to revolutionize many areas of medicine and our understanding of the progression of many diseases.
A unique trial will test the combination of two powerful and targeted breast cancer drugs, determining their safety and tolerability in Phase I and the overall response rate in Phase II.
New hope for patients with no bone marrow donor match
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Which studies from the American Society of Hematology’s annual meeting will make big impacts in 2015? Here are five papers that could change the way you practice medicine.
Early study results show significant improvement for young adult acute lymphoblastic leukemia patients on pediatric treatment regimen as compared to conventional adult regimens.
Cleveland Clinic/North American Cooperative Group phase II study shows improved overall response rate with combination therapy in certain patient subgroups with myelodysplastic syndromes and myelomonocytic leukemia.
Seattle Genetics has developed a novel antibody-drug conjugate that shows promise in treating patients with CD33-positive acute myeloid leukemia. SGN-CD33A targets cells expressing CD33.
Learn about featured clinical trials currently enrolling or search our trials database.
Cleveland Clinic research initiatives answer critical questions about the origin and treatment of blood disorders. These initiatives will be on display at the 56th Annual Meeting of the American Society of Hematology.